Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-2

TAK overview →Track this catalyst
Indication
Generalized Pustular Psoriasis; Erythrodermic Psoriasis

Other upcoming events for TAK

Phase 2 StartPhase 2 Start: An Open-Label, Single-Arm, Phase 2a Trial to Evaluate the Safety, Tolerability, PK, and Mechanism of
Phase 2 StartPhase 2 Start: A Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase 2 Trial to Evaluate the Safety an
Phase 3 ReadoutPhase 3 Topline: A Double-blind, Placebo-Controlled, Randomized Withdrawal Trial to Evaluate the Efficacy and Safety
Phase 3 ReadoutPhase 3 Topline: A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line T
Phase 3 ReadoutPhase 3 Topline: An Open-label, Single-arm Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

  • 200 free AI credits / month to run live multi-agent analysis
  • Watchlist, catalyst alerts & the biotech event calendar
  • Full pipeline, financials & FDA data on every company
Start Free
    Phase 3 Topline: A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-2 — TAK Phase 3 Readout | BioSniper